Sign in
Taking people in United StatesPhase 2

Lactobacillus rhamnosus GG bladder wash versus saline for urinary infections after spinal cord injury

Compares a bladder wash with Lactobacillus rhamnosusGG to saline in adults with neurogenic bladder.

Key facts

Who runs it
Medstar Health Research Institute
Where
Washington D.C., United StatesSee the site
Trial code
Registry title
Intravesical LGG VS Saline Bladder Wash RCT
Status
Recruiting
Phase
Phase 2
People taking part
120 people, planned
Started
13 Jun 2022
Expected to end
31 Dec 2026
Type of study
Interventional, 4 groups
Treatments tested
  • Lactobacillus RhamnosusGG
  • Saline bladder wash
Record updated
29 August 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a spinal cord injury and a bladder problem caused by nerve damage, who empty their bladder with a catheter. It compares two bladder washes meant to prevent urinary tract infections.

Age
18 years and older
Sex
All sexes
Disease stage
Spinal cord injury for at least 6 months, with nerve-related bladder problems (NLUTD) confirmed by the SCI doctor or urologist. People must live in the community, not in a hospital.
Earlier treatment
People must use intermittent catheterization to empty the bladder. People cannot join if they take antibiotics to prevent infection, took any oral antibiotics in the past 2 weeks, or put agents into the bladder (such as gentamycin, saline or Lactobacillus).

Main reasons for not taking part

  • Other known urinary or genital problems, such as urine flowing back to the kidneys or bladder or kidney stones
  • Weak immune system (immunodeficiency)
  • Active cancer, or cancer within the past 5 years, or active autoimmune disease
  • Mental or psychological conditions that affect following instructions
  • Prior bladder use of LGG® within 6 months, or being in another study that would affect results

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Age ≥18 years
  • SCI at least 6 months duration
  • NLUTD (as determined by their SCI physician or urologist)
  • Utilizing intermittent catheterization for bladder management; and
  • Community dwelling (discharged from the acute care setting)

Who cannot take part

  • 6 months since prior exposure to intravesical LGG®; and
  • Psychologic or psychiatric conditions influencing the ability to follow instructions
  • Active cancer (or within 5 years) or active autoimmune disorder
  • Known genitourinary pathology beyond neuropathic bladder (i.e., vesicoureteral reflux, bladder or kidney stones, etc.)
  • Use of prophylactic antibiotics
  • Instillation of intravesical agents (e.g., gentamycin, saline; or Lactobacillus)
  • Immunodeficiency
  • Any oral antibiotics within the past 2 weeks
  • Participation in another study in which results would be confounded

This trial is currently available in United States.

  • MedStar National Rehabilitation HospitalWashington D.C., United StatesContact: Allison M Maxwell, BATaking people

About the trial

What the trial wants to find out

This is the first ever comparative effectiveness study of an antibiotic-sparing novel self-management intervention to prevent complicated urinary tract infection (UTI).

The 4 groups in the trial

  • Intravesical Lactobacillus RhamnosusGG and Bladder Wash (Treatment Phase)Treatment being tested

    LGG® (Culturelle Probiotic LGG®) will be used. This is the product we have used in the past and for which we have demonstrated safety, tolerability, and preliminary efficacy. For the LGG® instillation in response to trigger symptoms, participants will be instructed to mix the contents of 1 LGG® capsule into 45 cc sterile 0.9% saline. After mixing, participants will draw up the 45cc liquid LGG® mixture into a 60cc syringe and instill via the intermittent catheter after the last catheterization prior to going to bed. Participants will be asked to return any remaining capsules at the end of the study. Participants will be instructed to complete the USQNB-IC at the time of symptoms (in real time) and daily during instillations for 2 days after the final instillation. Subjects will remain in this phase 6 months.

    Treatment: Lactobacillus RhamnosusGG

  • Intravesical Bladder Wash (Treatment Phase)Other group

    Participants will draw up the 45cc of normal saline into a 60cc syringe and instill via the intermittent catheter after the last catheterization prior to going to bed after trigger symptoms occur. Participants will be instructed to complete the USQNB-IC at the time of symptoms (in real time) and daily during instillations for 2 days after the final instillation. Subjects will remain in this phase 6 months.

    Treatment: Saline bladder wash

  • Intravesical Lactobacillus RhamnosusGG and Bladder Wash (Prophylaxis Phase)Treatment being tested

    LGG® (Culturelle Probiotic LGG®) will be used. This is the product we have used in the past and for which we have demonstrated safety, tolerability, and preliminary efficacy. For the LGG® instillation in response to trigger symptoms, participants will be instructed to mix the contents of 1 LGG® capsule into 45 cc sterile 0.9% saline. After mixing, participants will draw up the 45cc liquid LGG® mixture into a 60cc syringe and instill via the intermittent catheter after the last catheterization prior to going to bed. They will then instill the LGG® mixture every 2 days for the remainder of the 6 months. Participants will be asked to return any remaining capsules at the end of the study. Participants will be instructed to complete the USQNB-IC at the time of symptoms (in real time) and biweekly post-instillation. Subjects will remain in this phase 6 months.

    Treatment: Lactobacillus RhamnosusGG

  • Intravesical Bladder Wash (Prophylaxis Phase)Other group

    Participants will draw up the 45cc of normal saline into a 60cc syringe and instill via the intermittent catheter after the last catheterization prior to going to bed after trigger symptoms occur. They will then instill the saline BW every 2 days for the remainder of the 6 months. Participants will be instructed to complete the USQNB-IC at the time of symptoms (in real time) and biweekly post-instillation. Subjects will remain in this phase 6 months.

    Treatment: Saline bladder wash

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Intravesical Lactobacillus rhamnosusGG Versus Saline Bladder Wash: A Randomized, Controlled, Comparative Effectiveness Clinical Trial
Plain-language title
Lactobacillus rhamnosus GG bladder wash versus saline for urinary infections after spinal cord injuryGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
29 August 2025